AcureX Biosciences
Acurex Biosciences is dedicated to developing therapeutics that fundamentally modify the course of neurodegenerative diseases, aiming to slow or stop disease progression. Their platform is based on a Stanford University breakthrough discovery that identifies druggable targets for Parkinson’s disease. Supported by funding from prestigious institutions and foundations, Acurex is advancing a pipeline of early-stage neurology drug candidates, including their lead drug candidate CU-13001, an oral, brain-penetrant small molecule designed for Parkinson’s Disease.
Industries
Nr. of Employees
small (1-50)
AcureX Biosciences
Products
Oral brain-penetrant 15-lipoxygenase inhibitor (lead candidate)
An orally bioavailable, brain-penetrant small molecule designed to inhibit 15-lipoxygenase to reduce lipid-peroxidation products and downstream PD-related pathologies; in preclinical development and undergoing IND-enabling activities.
Selective CaV3.2 antagonist program
A discovery-stage program comprising selective antagonists of the CaV3.2 voltage-gated calcium channel intended as a starting point for lead identification and optimization for symptomatic or disease-modifying effects in neurological disorders.
Pan T-type calcium channel antagonist (IND-ready program)
A highly selective pan T-type calcium channel antagonist with favorable drug-like properties advanced to IND-enabling readiness and positioned for external development partnerships.
Oral brain-penetrant 15-lipoxygenase inhibitor (lead candidate)
An orally bioavailable, brain-penetrant small molecule designed to inhibit 15-lipoxygenase to reduce lipid-peroxidation products and downstream PD-related pathologies; in preclinical development and undergoing IND-enabling activities.
Selective CaV3.2 antagonist program
A discovery-stage program comprising selective antagonists of the CaV3.2 voltage-gated calcium channel intended as a starting point for lead identification and optimization for symptomatic or disease-modifying effects in neurological disorders.
Pan T-type calcium channel antagonist (IND-ready program)
A highly selective pan T-type calcium channel antagonist with favorable drug-like properties advanced to IND-enabling readiness and positioned for external development partnerships.
Services
In-house drug discovery and preclinical development
End-to-end discovery and preclinical progression of small-molecule CNS programs, including target identification, lead optimization, and efficacy testing in disease-relevant models.
Biomarker assay development
Development and validation of blood-based Miro1 ELISA assays using monoclonal antibodies for measurement in PBMCs to support translational studies and clinical endpoints.
Collaborative partnering and program licensing
Seeking partnerships to advance select programs (e.g., T-type channel program) through later-stage development and commercialization.
IND-enabling study execution
Conducting studies and program activities required to support IND submissions and initiation of first-in-human trials.
In-house drug discovery and preclinical development
End-to-end discovery and preclinical progression of small-molecule CNS programs, including target identification, lead optimization, and efficacy testing in disease-relevant models.
Biomarker assay development
Development and validation of blood-based Miro1 ELISA assays using monoclonal antibodies for measurement in PBMCs to support translational studies and clinical endpoints.
Collaborative partnering and program licensing
Seeking partnerships to advance select programs (e.g., T-type channel program) through later-stage development and commercialization.
IND-enabling study execution
Conducting studies and program activities required to support IND submissions and initiation of first-in-human trials.
Expertise Areas
- Neurodegenerative drug discovery
- Mitophagy-focused screening and target identification
- Biomarker discovery and assay development for mitochondrial dysfunction
- Small-molecule CNS drug development and blood–brain barrier penetration
Key Technologies
- High-throughput phenotypic screening
- Miro1-based biomarker assays
- ELISA using monoclonal antibodies
- Patient-derived neuronal models